Adage Capital Partners Gp, L.L.C. Mereo Biopharma Group PLC Transaction History

Adage Capital Partners Gp, L.L.C.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$2.25 - $3.76 $15.8 Million - $26.4 Million	-7,014,257 Reduced 80.48%	1,700,756 $3.83 Million
Q4 2024 Feb 14, 2025	SELL	$3.29 - $4.62 $3.29 Million - $4.62 Million	-1,000,000 Reduced 10.29%	8,715,013 $30.5 Million
Q3 2024 Nov 14, 2024	SELL	$3.45 - $4.87 $7.16 Million - $10.1 Million	-2,076,297 Reduced 17.61%	9,715,013 $39.9 Million
Q2 2024 Aug 14, 2024	BUY	$2.58 - $4.25 $6.35 Million - $10.5 Million	2,462,571 Added 26.4%	11,791,310 $42.4 Million
Q1 2024 May 15, 2024	BUY	$2.3 - $4.05 $15.4 Million - $27 Million	6,678,739 Added 252.03%	9,328,739 $30.8 Million
Q4 2023 Feb 14, 2024	BUY	$1.19 - $2.42 $2.2 Million - $4.48 Million	1,850,000 Added 231.25%	2,650,000 $6.12 Million
Q3 2023 Nov 14, 2023	BUY	$1.15 - $1.67 $919,999 - $1.34 Million	800,000 New	800,000 $1.03 Million
Q1 2022 May 16, 2022	SELL	$1.04 - $1.7 $1.04 Million - $1.7 Million	-1,000,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$2.2 - $3.17 $2.2 Million - $3.17 Million	1,000,000 New	1,000,000 $2.42 Million

98.2M

2.28M

761K

Ticker MREO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,986,000
Market Cap $207M
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.